Trial Profile

Phase 3, open-label trial of pneumococcal 13-valent CRM197 vaccine conjugate [Prevnar 13] in children aged 5-10 years who had previously been vaccinated for the prevention of pneumococcal disease with pneumococcal 7-valent CRM197 vaccine conjugate [Prevnar], and vaccine-naive children and adolescents aged 10-17 years

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 Feb 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Mar 2012 New trial record
12 Mar 2012 Results published in a Pfizer media release and presented at the 8th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com